scholarly journals Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases

Cancers ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 241
Author(s):  
Valentina Giannini ◽  
Laura Pusceddu ◽  
Arianna Defeudis ◽  
Giulia Nicoletti ◽  
Giovanni Cappello ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
First Line ◽  
Colorectal Cancer Liver Metastases ◽  
Predictive Values ◽  
Progression Of Disease ◽  
Folfox Chemotherapy ◽  
Colorectal Cancer Patients ◽  
Sensitivity Specificity ◽  
Radiomics Signature

The purpose of this paper is to develop and validate a delta-radiomics score to predict the response of individual colorectal cancer liver metastases (lmCRC) to first-line FOLFOX chemotherapy. Three hundred one lmCRC were manually segmented on both CT performed at baseline and after the first cycle of first-line FOLFOX, and 107 radiomics features were computed by subtracting textural features of CT at baseline from those at timepoint 1 (TP1). LmCRC were classified as nonresponders (R−) if they showed progression of disease (PD), according to RECIST1.1, before 8 months, and as responders (R+), otherwise. After feature selection, we developed a decision tree statistical model trained using all lmCRC coming from one hospital. The final output was a delta-radiomics signature subsequently validated on an external dataset. Sensitivity, specificity, positive (PPV), and negative (NPV) predictive values in correctly classifying individual lesions were assessed on both datasets. Per-lesion sensitivity, specificity, PPV, and NPV were 99%, 94%, 95%, 99%, 85%, 92%, 90%, and 87%, respectively, in the training and validation datasets. The delta-radiomics signature was able to reliably predict R− lmCRC, which were wrongly classified by lesion RECIST as R+ at TP1, (93%, averaging training and validation set, versus 67% of RECIST). The delta-radiomics signature developed in this study can reliably predict the response of individual lmCRC to oxaliplatin-based chemotherapy. Lesions forecasted as poor or nonresponders by the signature could be further investigated, potentially paving the way to lesion-specific therapies.

scholarly journals Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Sébastien Tabariès ◽  
Matthew G. Annis ◽  
Anthoula Lazaris ◽  
Stephanie K. Petrillo ◽  
Jennifer Huxham ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Liver Metastases ◽  
Growth Pattern ◽  
Treatment Strategies ◽  
Immunohistochemical Analysis ◽  
Colorectal Cancer Liver Metastases ◽  
Colorectal Cancer Liver Metastasis ◽  
Breast Cancer Liver Metastasis ◽  
Colorectal Cancer Patients

AbstractClaudin-2 promotes breast cancer liver metastasis by enabling seeding and early cancer cell survival. We now demonstrate that Claudin-2 is functionally required for colorectal cancer liver metastasis and that Claudin-2 expression in primary colorectal cancers is associated with poor overall and liver metastasis-free survival. We have examined the role of Claudin-2, and other claudin family members, as potential prognostic biomarkers of the desmoplastic and replacement histopathological growth pattern associated with colorectal cancer liver metastases. Immunohistochemical analysis revealed higher Claudin-2 levels in replacement type metastases when compared to those with desmoplastic features. In contrast, Claudin-8 was highly expressed in desmoplastic colorectal cancer liver metastases. Similar observations were made following immunohistochemical staining of patient-derived xenografts (PDXs) that we have established, which faithfully retain the histopathology of desmoplastic or replacement type colorectal cancer liver metastases. We provide evidence that Claudin-2 status in patient-derived extracellular vesicles may serve as a relevant prognostic biomarker to predict whether colorectal cancer patients have developed replacement type liver metastases. Such a biomarker will be a valuable tool in designing optimal treatment strategies to better manage patients with colorectal cancer liver metastases.

Effectiveness of neoadjuvant FOLFOX chemotherapy in Japanese patients with colorectal cancer liver metastases

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 15097-15097
Author(s):  
H. Baba ◽  
T. Beppu ◽  
S. Honda ◽  
N. Yoshida ◽  
H. Komori ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Japanese Patients ◽  
Colorectal Cancer Liver Metastases ◽  
Folfox Chemotherapy

Identification of the biomarkers for the prediction of efficacy in the first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14026-e14026
Author(s):  
Ying Yuan ◽  
Hong Shen ◽  
Mo-Dan Li ◽  
Chun-Wen Tan ◽  
Jie-Kai Yu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Neural Networks ◽  
Artificial Neural Networks ◽  
Metastatic Colorectal Cancer ◽  
Protein Patterns ◽  
First Line ◽  
Folfox Chemotherapy ◽  
Colorectal Cancer Patients ◽  
Line Chemotherapy ◽  
Tof Ms

e14026 Background: For patients with metastatic colorectal cancer, both FOLFOX regimen and FOLFIRI regimen are considered as first-line choices. However, only about half of patients could have an obvious response, and there are no clinically useful markers that could predict the response to these regimens respectively. A major clinical challenge is to identify the subset of patients who could benefit from those regimens. We aimed at identifying serum protein patterns which could predict the efficacy of chemotherapy. Methods: Serum from 70 patients diagnosed as metastatic colorectal cancer before first-line chemotherapy were collected and analyzed for protein patterns using artificial neural networks (ANN) analysis of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Among the 70 cases, 44 patients received FOLFOX chemotherapy, while the other 26 patients received FOLFIRI chemotherapy. After four cycles of the treatment, RECIST criteria were used to define the responders (R) and non-responders (NR). Results: With the method of SELDI-TOF-MS,a potential predicting pattern consisting of 6 biomarkers (9,298m/z, 9,282m/z, 4,606m/z, 9,198m/z, 7,775m/z and 2,266m/z) was identified in the patients receiving FOLFOX chemotherapy. Using this predicting pattern, the responders could be separated from the non-responders with a sensitivity of 92.9%, and a specificity of 81.3%. Another potential predicting pattern that consisted of 7 biomarkers (4,321m/z, 4,305m/z, 2,648m/z, 2,952m/z, 4,121m/z, 4,292m/z and 3,980 m/z) was identified in the patients who have received FOLFIRI chemotherapy. Using this predicting pattern, the responders could be separated from the non-responders with a sensitivity of 92.3% and a specificity of 92.3 %. Conclusions: Two potential patterns for the prediction of efficacy of FOLFOX or FOLFIRI chemotherapy were established in this preliminary study. These protein patterns could be helpful for oncologists to make a decision in selecting suitable first-line regimens for metastatic colorectal cancer patients.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3553-3553
Author(s):  
Dominik Paul Modest ◽  
Meinolf Karthaus ◽  
Stefan Kasper ◽  
Nicolas Moosmann ◽  
Verena Keitel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Primary Endpoint ◽  
Specific Treatment ◽  
Progression Free Survival ◽  
Favourable Outcome ◽  
Wild Type ◽  
Open Label ◽  
Colorectal Cancer Liver Metastases ◽  
Colorectal Cancer Patients

3553 Background: This trial investigates the addition of panitumumab to chemotherapy with fluorouracil/ folinic acid and oxaliplatin (FOLFOX) in a 2:1 randomized, controlled, open label, phase II trial in RAS wild-type colorectal cancer patients with R0/1-resected liver metastases. Methods: The primary endpoint was progression-free survival (PFS) two years after randomisation. The experimental arm (12 wks of biweekly mFOLFOX6 plus panitumumab followed by 12 wks of panitumumab alone) was considered active if the 2-year-PFS rate was ≥65%. Based on historical data, a 2-year-PFS rate of 50% was estimated in the control arm (12 wks of biweekly FOLFOX). The trial was performed with a power of 80% and an alpha of 0.05. Secondary endpoints included overall survival (OS) and toxicity. The trial is registered with ClinicalTrials.gov, NCT01384994. Results: The full analysis set consists of 70 patients (pts) in the experimental arm and 36 pts in the control arm. The 2-year-PFS rate was 34.3% with FOLFOX plus panitumumab and failed to meet the primary endpoint. The 2-year-PFS rate in the control arm was 25%. In the experimental arm, a more favourable outcome was observed with regard to PFS (HR: 0.72, 95%CI 0.45-1.17; P = 0.18) and OS (HR: 0.76 (95% CI 0.34-1.71, P = 0.51) which did, however, not reach the level of significance. Updated data including toxicity and subgroup analyses might be presented at the meeting Conclusions: The PARLIM trial clearly failed to demonstrate a PFS rate of 65% after resection of colorectal liver metastases 2 years after randomisation, potentially indicating that the generally high frequency of recurrence and the choice of primary endpoint did not correspond in this study population. However, a trend for improved PFS and OS by the addition of panitumumab to 12 wks of FOLFOX followed by 12 wks panitumumab maintenance therapy may support future trials with ant-EGFR antibodies in this specific treatment setting. Clinical trial information: NCT01384994.

Sign in / Sign up

Export Citation Format

Share Document